Quarterly report pursuant to Section 13 or 15(d)

Shareholders' Equity (Details)

v3.21.2
Shareholders' Equity (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Oct. 09, 2017
Feb. 25, 2021
Feb. 08, 2021
Jan. 26, 2021
Sep. 27, 2020
Sep. 30, 2021
Sep. 30, 2021
Dec. 31, 2020
Shareholders' Equity (Details) [Line Items]                
Unregistered shares of common stock (in Shares)       669,980        
Stock consideration       $ 1,060,150        
Options for purchase (in Shares)     10,000          
Exercise price (in Dollars per share)     $ 1.45          
Total exercised     $ 14,500       $ 14,500  
Warrants for purchase (in Shares)   712,500            
Warrant exercise fee (in Dollars per share)   $ 2            
Total proceeds           $ 170,000 170,000  
Total cost           $ 548,100 $ 548,100  
Common stock, shares outstanding (in Shares)           20,448,156 20,448,156 14,393,100
Outstanding options intrinsic value           $ 6,367,096 $ 6,367,096  
Option purchased             1,042,000  
Weighted average fair value             $ 2,505,573  
Weighted average fair value share price (in Dollars per share)           $ 2.4 $ 2.4  
Weighted average remaining vesting period             1 year 9 months 21 days  
Unrecognized compensation expense             $ 3,272,012  
Equity Incentive Plan [Member]                
Shareholders' Equity (Details) [Line Items]                
Common stock shares available for issuance (in Shares)           139,686 139,686  
Consultant [Member]                
Shareholders' Equity (Details) [Line Items]                
Fair value of assumptions, description             This table includes warrants to purchase 144,851 shares of common stock issued to consultants, including the 53,146 shares of common stock issued during the nine months ended September 30, 2021, with a total fair value of $149,581 at time of issue, calculated using the Black Scholes model assuming an underlying security values of ranging between $1.30 and $2.62, volatility rate ranging between 103.8% and 110.24%, a risk-free rate ranging between 0.43% and 0.49%, and an expected term of 5.75 years. In the three and nine months ended September 30, 2021, the Company recognized $92,892 and $170,254 in expense associated with these warrants, respectively, with $55,502 remaining to be recognized at September 30, 2021.  
Consultants Services [Member]                
Shareholders' Equity (Details) [Line Items]                
Share issued (in Shares)           620,000 620,000  
Total proceeds           $ 1,674,000 $ 1,674,000  
Common stock, shares outstanding (in Shares)           3,561,180 3,561,180  
Warrant [Member]                
Shareholders' Equity (Details) [Line Items]                
Total exercised   $ 1,425,000            
Keystone Equity Purchase Agreement [Member]                
Shareholders' Equity (Details) [Line Items]                
Share issued (in Shares)           205,762 1,645,907  
Total proceeds           $ 500,000 $ 3,850,000  
Securities Purchase Agreement [Member]                
Shareholders' Equity (Details) [Line Items]                
Share issued (in Shares)           1,666,668 2,366,669  
Total proceeds           $ 5,000,004 $ 7,100,007  
Common Stock [Member]                
Shareholders' Equity (Details) [Line Items]                
Weighted average remaining vesting period             2 years 7 months 9 days  
2017 Equity Incentive Plan [Member]                
Shareholders' Equity (Details) [Line Items]                
Common stock issued, shares (in Shares) 1,750,000       7,500,000   489,437